Indian pharmaceutical companies continue to make strategic moves in global markets, with Ajanta Pharma leading Wednesday's gainers following a major licensing agreement, while Zydus and Emcure reported significant regulatory developments.

Ajanta Pharma Stock Surges on Biocon Partnership

Shares of Ajanta Pharma gained 5.10% on Wednesday, trading at ₹2,804.80, following the announcement of an in-licensing agreement with Biocon for semaglutide, a GLP-1 receptor agonist. The stock has surged over 11% in the last month, reducing its year-to-date losses to 6.50%.

Biocon will supply semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in three countries across Africa, Central Asia and the Middle East. The product patent expires in most of these markets in March 2026, with Ajanta planning commercialization after receiving regulatory approvals expected in late 2026 or early 2027.

"GLP-1 therapies have witnessed rapid global acceptance and have emerged as blockbuster products across the world. We are excited to partner with Biocon for semaglutide and take this important therapy to the markets where Ajanta has strong on-ground presence and deep reach," said Yogesh Agarwal, Managing Director of Ajanta Pharma.

Zydus Expands US Biosimilar Portfolio

Zydus Lifesciences has secured a significant partnership through its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates. The company entered into a strategic agreement with Bioeq AG, a Swiss biopharmaceutical company, for the licensing, supply and commercialisation of NUFYMCO in the US market.

This transaction represents an expansion of Zydus' US biosimilar business, building on its recent partnership with Formycon AG for a biosimilar of Keytruda (Pembrolizumab). The USFDA approved the Biologics License Application (BLA) for NUFYMCO on December 18.

Emcure Receives Positive USFDA Facility Classification

Emcure Pharmaceuticals has received favorable regulatory news from the United States Food and Drug Administration. The USFDA issued a No Action Indicated (NAI) classification for the company's facility located in Kadu, Surendranagar, following the completion of a regulatory inspection.

The NAI classification indicates that the facility met USFDA standards during the inspection process, providing regulatory confidence for the company's manufacturing operations and potential US market activities.

Zydus Lifesciences has entered into a strategic partnership with Bioeq to secure US commercialization rights for Nufymco, marking a significant development in the company's international expansion strategy. The collaboration follows the successful approval of Nufymco's Biologics License Application (BLA) by the US Food and Drug Administration (FDA) on December 18, 2025.

USFDA Approval Milestone

The partnership gains particular significance with the FDA's approval of Nufymco's BLA on December 18, 2025. This regulatory clearance represents a crucial step in bringing the biologic product to the US market.

Strategic Partnership Framework

The collaboration with Bioeq positions Zydus Lifesciences to leverage specialized expertise for the US market entry of Nufymco. This partnership structure allows the company to access established distribution networks and regulatory knowledge specific to the American pharmaceutical landscape.

Market Expansion Implications

The partnership represents Zydus Lifesciences' continued focus on international market expansion through strategic alliances. By securing US rights to Nufymco through this collaboration, the company demonstrates its commitment to bringing innovative biologic treatments to American patients while leveraging partner expertise for market penetration.